Q-omics provides the consensus-scored DLEU1 profile across patient tissues and cancer cell-line models. DLEU1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DLEU1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, DLEU1 RNA expression shows 20,585 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, KIRC, and ACC as cancer lineages where DLEU1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLEU1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLEU1 survival associations across molecular data types. DLEU1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLEU1 RNA expression–survival associations across cancer types. High DLEU1 expression shows unfavorable associations in BLCA, ACC, UVM, CESC, KICH and KIRP. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for DLEU1 RNA expression.
This table summarizes DLEU1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DLEU1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLEU1 shows higher tumor expression in KIRC, HNSC, STAD, COAD, BLCA and LUSC. The KIRC box plot shows higher DLEU1 RNA expression in tumor versus normal tissue (log2 FC = +0.571, t-test p < 0.001).
This table shows molecular features associated with DLEU1 in patient tissues and cancer cell lines. In patient samples, DLEU1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DLEU1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
